Pearls from Clinical Practice: Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis An EBGI x GIJC Collaboration Section Discussion Summaries

##plugins.themes.academic_pro.article.sidebar##

Published Apr 26, 2023
https://doi.org/10.52697/gijournal.v3i1.43
Download
Statistic

Downloads

Download data is not yet available.
Vol. 3 (2023)

##plugins.themes.academic_pro.article.main##

Noor Syed
Sophia Dar
Joseph Sleiman
Allon Kahn
Philip Schoenfeld

Abstract

Dupilumab is a monoclonal antibody that has been a longstanding treatment of several allergic diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Recently, dupilumab was approved for treatment of Eosinophilic esophagitis (EoE) by the Federal Drug Administration (FDA).


Herein we summarize the @GIJournal discussion on April 2 2023, during which we presented the article: Dellon et. al titled, “Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis” published in NEJM, December 2022.


The role of dupilumab, its efficacy, side effects and monitoring were discussed with our expert, Dr. Philiip Schoenfeld (PS) and the session was moderated by Dr. Allon Kahn (AK). EBGI Ambassadors Dr. Noor Syed (NS) and Dr. Sophia Dar (SD) collaborated on the discussion. Questions were administered by @ACG_EBGI managed by Dr. Sophia Dar (SD). Questions and slides were prepared by Dr. Sophia Dar and Dr. Joseph Sleiman.

##plugins.themes.academic_pro.article.details##

How to Cite
Syed, N., Dar, S., Sleiman, J., Kahn, A., & Schoenfeld, P. (2023). Pearls from Clinical Practice: Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis : An EBGI x GIJC Collaboration. @Gijournal, 3(1). https://doi.org/10.52697/gijournal.v3i1.43

Most read articles by the same author(s)